Furthermore, molecular workup of a follow-up tissue or liquid biopsy at the time of TKI failure is gaining importance for the management of ALK+ NSCLC, since it can reveal patient-specific resistance mechanisms and guide subsequent therapeutic decisions [9,10,11]. This evidence concerns the gene ALK and non-small cell lung carcinoma.